Immunodiagnostic Systems Holdings plc announced that it will provide contract manufacturing services to The Binding Site (TBS) related to their SARS-CoV-2 Antibody ELISA test, which was launched in Europe and other markets which accept the CE mark today. The test has also been submitted for rapid FDA approval. The antibody coated ELISA microtiter plates for this test will be produced at the IDS facility in Boldon, UK, where IDS has the capacity to provide up to two million tests per month for TBS. The process involves coating the microtiter plates with the trimeric spike protein developed by TBS and the University of Birmingham (UoB). The plates are then washed and stabilized using proprietary IDS reagents.